Treatment of Juvenile Idiopathic Arthritis in the Biologics Era

被引：2
作者：
Haas, J. -P. [1 ]
机构：
[1] Deutsch Zentrum Kinder & Jugendrheumatol Garmisch, D-82467 Garmisch Partenkirchen, Germany
来源：
AKTUELLE RHEUMATOLOGIE | 2015年 / 40卷 / 04期
关键词：
juvenile Idiopathic Arthritis; childrens' rheumatology; multidisciplinary therapy; biologics;
D O I：
10.1055/s-0035-1548859
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Quality and results of treatment in rheumatic diseases of childhood and adolescent have made substancial progress within the last decade. This has been determined through different factors: (i) medical treatment has gained effectiveness by the introduction of new drugs, (ii) provision of units specialised in childhood rheumatology has been substancially improved, (iii) multidisciplinary concepts of treatment and educational programmes have been established in specialised centres, (iv) functional treatment has been developed further with the introduction of even sports therapy. This review summarises some of the important developments using juvenile idiopathic arthritis as an example.
引用
收藏
页码：275 / 279
页数：5
相关论文
共 35 条
  • [1] Haas J.P., Hafner R., Truckenbrodt H., Juvenile Idiopathische Arthritis, pp. 377-400, (2012)
  • [2] Haas J.P., Hafner R., Truckenbrodt H., Weitere Rheumatische Erkankungen im Kindes- und Jugendalter, pp. 401-431, (2012)
  • [3] Petty R.E., Southwood T.R., Baum J., Baum, Et al., Revision of the proposed classification criteria for juvenile idiopathic arthritis, The Journal of Rheumatology, 25, pp. 1991-1994, (1997)
  • [4] Krumrey-Langkammerer M., Hafner R., Evaluation of the ILAR criteria for juvenile idiopathic arthritis, The Journal of Rheumatology, 28, pp. 2544-2547, (2001)
  • [5] Beukelman T., Patkar N.M., Saag K.G., Saag, Et al., American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care & Research, 63, pp. 465-482, (2011)
  • [6] Dueckers G., Guellac N., Arbogast M., Arbogast, Et al., Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis, Clinical Immunology, 142, pp. 176-193, (2012)
  • [7] Ringold S., Weiss P.F., Beukelman T., Beukelman, Et al., 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications, Arthritis Care & Research, 65, pp. 1551-1563, (2013)
  • [8] Truckenbrodt H., Hafner R., Methotrexate therapy in juvenile rheumatoid arthritis: A retrospective study, Arthritis and Rheumatism, 29, pp. 801-807, (1986)
  • [9] Horneff G., Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7<sup>th</sup> Worlitzer Expertengesprache 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie, Zeitschrift fur Rheumatologie, 65, pp. 152-156, (2006)
  • [10] Prieur A.M., Bremard-Oury C., Griscelli C., Griscelli, Et al., Prognosis of the systemic forms of juvenile chronic arthritis. Apropos of 100 cases, Archives Francaises de Pediatrie, 41, pp. 91-97, (1984)
1234